Bal Pharma Limited

To,

The Manager-Listing

National Stock Exchange of India Ltd

Mumbai.

12.2.2018

The Manager-Listing

BSE Limited

Mumbai.

Dear Sir,

Sub : Submission of newspaper Advertisement-Reg Investor Education and Protection Fund (Accounting, Audit, Transfer and Refund) Rules,2016.

Ref : Regulation 47 of the SEBI(LODR) Regulations,2015.

With reference to the above, we are submitting to the exchange copies of the news paper advertisement appearing on Financial Express (English language) and Sanjavani (Kannada Language) dated 10.02.2018, intimating to the shareholders of the Company , provisions relating to the transfer of shares of those shareholders who have not encased their dividend for the last 7 consecutive years to IEPF authority .

Please note that we have also sent personal intimations to all our shareholders whose shares qualify for such transfer, to encash their dividend on time so that we may desist from transfer of their shares to IEPF authority.

We have also uploaded the list of shareholders whose shares are liable to be transferred to IEPF authority, on our website i.e www.balpharma.com.

Thanking You

For Bal Pharma Limited

Authorised Signatory

CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : info@balpharma.com Website : www.balpharma.com
CIN # L85110KA1987PLC008368
REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820

Intertek

014

Financial Express dt. 10/2/18

BAL PHARMA LIMITED

CIN #L85110KA1987PLC008368
Regd. Office: # 21&22, Bommasandra Industrial Area,
Bangalore - 560099. Tel: (080) 41379500. Fax: (080) 22354057
email: investor@balpharma.com

NOTICE TO THE EQUITY SHAREHOLDERS OF THE COMPANY

Notice to the equity shareholders of the Company for transfer of equity shares to the investors education and protection fund (IEPF) suspense account.

This notice is issued pursuant to the provisions of the Investors Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (the IEPF Rules) notified by the Ministry of Corporate Affairs effective from 7th September, 2016 and as amended from time to time.

The IEPF rules, amongst other matters, contain provisions for transfer of all shares in respect of which dividend has not been paid or claimed by the shareholders for seven consecutive years or more, in the name of Investors Education and Protection Fund suspense account (IEPF Suspense account).

Accordingly, shares of those shareholders who have not en-cashed their dividend for seven consecutive years from 2008-09 will be transferred to the IEPF suspense account. Individual communication to this effect is being sent to the concerned shareholders at their available address for taking appropriate action(s). The Company has also uploaded the details of such shareholders and their shares which are due for transfer to the IEPF suspense account on its website i.e **www.balpharma.com**. Share holders can verify the details of un-encased dividends and the shares which are liable to be transferred to the IEPF suspense account, from the website.

Shareholders are requested to note that both the unclaimed dividend and the shares transferred to the IEPF authority / suspense account, including all benefits on such shares ,if any ,can be claimed back by them from IEPF authority, by following the procedure given on the website of IEPFA i.e. **http://iepf.gov.in/IEPFA/refund.html.**

With respect to the shares held in physical form, the Company would issue duplicate share certificate in lieu of original share certificate for the purpose of transfer to IEPFA and upon such issue, the original share certificate will stand automatically cancelled and be deemed non-negotiable. After issue of duplicate share certificates, the Company shall inform the depository by way of corporate action to convert the duplicate share certificates into DEMAT form and transfer in the favour of the Authority

For shares held in demat mode, the Company will process the transfer of shares through Depositories by way of Corporate Action in favour of IEPF Authority. The Shareholders may note that this Notice shall be treated as adequate notice in respect of issue of duplicate share certificate(s) by the Company for the purpose of transfer of shares to IEPF suspense account.

The shareholders may note that if no communication is received by the Company or the R&T agents i.e TSR Darashaw Limited from the concerned shareholders by March 10th, 2018 or any extension thereof, if any, the Company shall with a view to comply with the requirements set out in the IEPF rules, transfer the shares to IEPF suspense account by the due date without further notice.

For any clarification in the matter, please contact the R&T agents of the Company i.e TSR Darashaw Limited, 6-10, Haji Moosa Patrawala Ind Estate, 20 Dr. E. Moses Road, Near famous studio, Mahalakshmi (w), Mumbai - 400011, Phone: 022-66568484, Fax: 66568494, email: **csg-unit@tsrdarashaw.com.**

For Bal Pharma Limited
SHAILESH SIROYA
Managing Director

Place: **Bangalore**
Date : **05.02.2018**

INC 26 [Pursuant to rule 30 of the Companies (Incorporation) Rules, 2014]

SANJAY VORA 10/2/18

BAL PHARMA LIMITED

CIN #L85110KA1987PLC008368
Regd. Office: # 21&22, Bommasandra Industrial Area,
Bangalore - 560099. Tel: (080) 41379500, Fax: (080) 22354057
email: investor@balpharma.com

NOTICE TO THE EQUITY SHAREHOLDERS OF THE COMPANY

Notice to the equity shareholders of the Company for transfer of equity shares to the investors education and protection fund (IEPF) suspense account.

This notice is issued pursuant to the provisions of the Investors Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (the IEPF Rules) notified by the Ministry of Corporate Affairs effective from 7th September, 2016 and as amended from time to time.

The IEPF rules, amongst other matters, contain provisions for transfer of all shares in respect of which dividend has not been paid or claimed by the shareholders for seven consecutive years or more, in the name of Investors Education and Protection Fund suspense account (IEPF Suspense account).

Accordingly, shares of those shareholders who have not en-cashed their dividend for seven consecutive years from 2008-09 will be transferred to the IEPF suspense account. Individual communication to this effect is being sent to the concerned shareholders at their available address for taking appropriate action(s). The Company has also uploaded the details of such shareholders and their shares which are due for transfer to the IEPF suspense account on its website i.e **www.balpharma.com**. Share holders can verify the details of un-encased dividends and the shares which are liable to be transferred to the IEPF suspense account, from the website.

Shareholders are requested to note that both the unclaimed dividend and the shares transferred to the IEPF authority / suspense account, including all benefits on such shares ,if any ,can be claimed back by them from IEPF authority, by following the procedure given on the website of IEPFA i.e. http://iepf.gov.in/IEPFA/refund.html.

With respect to the shares held in physical form, the Company would issue duplicate share certificate in lieu of original share certificate for the purpose of transfer to IEPFA and upon such issue, the original share certificate will stand automatically cancelled and be deemed non-negotiable. After issue of duplicate share certificates, the Company shall inform the depository by way of corporate action to convert the duplicate share certificates into DEMAT form and transfer in the favour of the Authority.

For shares held in demat mode, the Company will process the transfer of shares through Depositories by way of Corporate Action in favour of IEPF Authority. The Shareholders may note that this Notice shall be treated as adequate notice in respect of issue of duplicate share certificate(s) by the Company for the purpose of transfer of shares to IEPF suspense account.

The shareholders may note that if no communication is received by the Company or the R&T agents i.e TSR Darashaw Limited from the concerned shareholders by March 10th, 2018 or any extension thereof, if any, the Company shall with a view to comply with the requirements set out in the IEPF rules, transfer the shares to IEPF suspense account by the due date without further notice.

For any clarification in the matter, please contact the R&T agents of the Company i.e TSR Darashaw Limited, 6-10, Haji Moosa Patrawala Ind Estate, 20 Dr. E. Moses Road, Near famous studio, Mahalakshmi (w), Mumbai - 400011. Phone: 022-66568484, Fax: 66568494, email: **csg-unit@tsrdarashaw.com.**

For Bal Pharma Limited
SHAILESH SIROYA
Managing Director

Place: **Bangalore**
Date : **05.02.2018**